多重血清免疫谱分析揭示循环LAG-3与高级别浆液性卵巢癌患者生存改善相关
本研究采用多重方法检测75例未治疗高级别浆液性卵巢癌患者血清中免疫检查点受体LAG-3、PD-1及48种细胞因子和趋化因子,发现血清LAG-3升高与无进展生存期和总生存期改善显著相关,而循环PD-1水平与临床结局基本无关,提示LAG-3可作为非侵入性预测标志物。
要点
- 血清LAG-3升高与高级别浆液性卵巢癌患者无进展生存期和总生存期改善显著相关。
- 循环PD-1水平与患者临床结局基本无关。
- IL-15表达降低与无进展生存期和总生存期改善相关。
核心结论
- 血清LAG-3是从多种趋化因子和细胞因子中识别出的与高级别浆液性卵巢癌生存改善最显著相关的免疫学因素。
- 这些发现提示LAG-3可作为非侵入性患者预测标志物用于改善高级别浆液性卵巢癌临床结局。
研究设计与样本
- 采用多重方法检测75例未治疗高级别浆液性卵巢癌患者血清样本中免疫检查点受体LAG-3、PD-1及48种常见细胞因子和趋化因子的循环水平。
主要发现
- 血清LAG-3升高与高级别浆液性卵巢癌无进展生存期和总生存期改善显著相关。
- 循环PD-1水平与患者临床结局基本无关。
- 细胞因子和趋化因子分析显示IL-15表达降低与无进展生存期和总生存期改善相关。
- IL-1α、IL-1Ra、IL-6、IL8和VEGF升高与术前CA-125水平显著相关。
- ROC分析显示血清LAG-3水平作为单药具有一致合理的预测能力。
关键数值与推荐
- 血清LAG-3升高与无进展生存期和总生存期改善显著相关。
- 循环PD-1水平与患者临床结局基本无关。
- IL-15表达降低与无进展生存期和总生存期改善相关。
- IL-1α、IL-1Ra、IL-6、IL8和VEGF升高与术前CA-125水平显著相关。
- ROC分析显示血清LAG-3水平作为单药具有一致合理的预测能力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High grade serous ovarian cancer (HGSOC) exhibits low response rates to clinically available immunotherapies. Nevertheless, emerging research has demonstrated that certain immune factors are predictive for HGSOC patient clinical outcomes, with our own groups previous work demonstrating that intratumoral levels of the immune checkpoint receptor LAG-3 is associated with improved patient survival. In this current study we sought to uncover non-invasive circulating immune prognostic and predictive signatures in HGSOC. METHODS: A multiplex approach was employed that examined circulating levels of immune checkpoint receptors LAG-3 and PD-1 along with 48 common cytokine and chemokines in a cohort of 75 HGSOC treatment naïve patient serum samples. RESULTS: Elevated serum LAG-3 was significantly associated with improved progression-free survival (PFS) and overall survival (OS) in HGSOC, while circulating PD-1 levels were largely unrelated with patient clinical outcomes. Cytokine and chemokine analysis revealed lower IL-15 expression correlated with improved PFS and OS, while increased IL-1α, IL-1Ra, IL-6, IL8 and VEGF were significantly associated with preoperative CA-125 levels. ROC analysis demonstrated that serum LAG-3 levels exhibited consistent reasonable predictability as a single agent. CONCLUSIONS: Serum-derived LAG-3 was identified out of a diverse array of chemokine and cytokines as the immune-based factor most significantly associated with improved HGSOC survival. These findings suggest that LAG-3 could be implemented as a non-invasive patient predictive marker for improved HGSOC clinical outcomes.
引用
- Eurich K, De La Cruz P, Laguna A, et al. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer. Gynecol Oncol. 2023. PMID: 37224792. doi:10.1016/j.ygyno.2023.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。